期刊文献+

肾透明细胞癌组织中转录因子19基因选择性剪接异构体的类型和表达特点 被引量:1

Types of alternative splice variants of transcription factor 19 and their expression patterns in clear cell renal cell carcinoma tissues
原文传递
导出
摘要 目的探讨人肾透明细胞癌(clear cell renal cell carcinoma,ccRCC)是否存在与细胞生长调节相关的转录因子19(TCF19)选择性剪接异构体,探索其表达特点及其与ccRCC发生的关系。方法通过选择性剪接数据库(alternative Spli-cing Database,ASD)对TCF19基因可能存在的选择性剪接异构体种类进行预测。设计可能存在的5种异构体引物,采用RT-PCR技术,在32例原发肾透明细胞癌的混合样本及癌旁组织的混合样本中分别检测预测异构体的表达,并对电泳所获条带进行克隆、测序。应用RT-PCR定量检测在各个组织样本中异构体TCF19-1、TCF19-3在原发肾癌及癌旁组织的表达差异。结果 ccRCC组织中存在2种新型TCF19替换剪接异构体(TCF19-1、TCF19-3)。RT-PCR检测结果发现这2种异构体在癌和癌旁组织中均表达,但TCF19-1在原发癌组织中表达率高于癌旁组织(P<0.001);TCF19-3在癌旁组织中的表达率与原发癌组织比较,差异无统计学意义(P=0.082)。结论首次发现ccRCC组织中存在2种TCF19选择性剪接异构体TCF19-1和TCF19-3,其中TCF19-1的表达可能与ccRCC有关。 Objective To study whether there is expression of the alternative splice variants of TCF19,a cell growth regulatory gene,in human clear cell renal cell carcinoma(ccRCC)tissues and their relationship with the development of ccRCC.Methods Alternative Splicing Database was used to predict the possible alternative splice variants of TCF19.Specific primers for amplifying the 5 predicted variants of TCF19 were designed and used to examine the corresponding variants in 32 ccRCC tissues and normal tissues adjacent to the tumors by RT-PCR technique.The amplicons were then cloned and sequenced.Quantitative RT-PCR was used to detect the expression differences of the variants between the primary renal cell carcinoma and adjacent tissues.Results Two new isoforms of TCF19(TCF19-1 and TCF19-3)were identified in the ccRCC and the adjacent tissues.RT-PCR results showed that TCF19-1 expression was significantly higher in the primary ccRCC tissues than that in the adjacent normal tissues(P0.001).And the expression of TCF19-3 in the primary tumor was only slightly higher than that in the adjacent tissues(P=0.082).Conclusion This study for the first time identifies the existence of two alternative splice isoforms of TCF-19,TCF19-1 and TCF19-3,in human ccRCC tissues,and the expression of TCF19-1 might be related to the development of ccRCC.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2010年第7期706-710,共5页 Academic Journal of Second Military Medical University
基金 国家自然科学基金(30872562) 上海市教育委员会科研创新项目(08ZZ39)~~
关键词 转录因子类 肾肿瘤 选择性剪接 异构体 transcription factors kidney neoplasms alternative splicing isoforms
  • 相关文献

参考文献10

  • 1顾方六,肾肿瘤[M]//吴阶平.泌尿外科学.上卷.济南:山东科学技术出版社,2004:895-896.
  • 2Liou L S,Shi T,Duan Z H,Sadhukhan P,Der S D,Novick A A,et al. Microarray gene expression profiling and analysis in renal cell carcinoma[J].BMC Urol, 2004,4: 9.
  • 3盛锡楠,李峻岭,郭军,赵小慧,朱军,储大同.重组人源化白细胞介素2治疗转移性肾癌的临床研究[J].中华肿瘤杂志,2008,30(2):129-133. 被引量:18
  • 4Escudier B, Hutson T, Stadler W M, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J].N Engl J Med,2007,356:125-134.
  • 5MotzerRJ, Huston T E, Tomczak P, Michaelson M D, Bukowski R M,Rixe O,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J].N Engl J Med, 2007,356:115-124.
  • 6周爱萍,何志嵩,于世英,张沂平,杜春霞,孙永昆,石远凯,王金万,那彦群,孙燕.索拉非尼治疗转移性肾癌的临床研究[J].中华泌尿外科杂志,2009,30(1):10-14. 被引量:54
  • 7TanX,ZhaiY,ChangW,Hou J,HeS,Lin L,et al. Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma[J].Int J Cancer, 2008,123 : 1080-1088.
  • 8Krishnan B R,Jamry I, Chaplin D D. Feature mapping of the HLA class I region: localization of the POUSF1 and TCF19 genes[J].Genomics, 1995,30:53-58.
  • 9Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S,et al. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer[J].Clin Cancer Res, 2002,8 : 2253-2259.
  • 10Wang Z,Lo H S, Yang H,Gere S, Hu Y,Buetow K H,et al. Computational analysis and experimental validation of tumor- associated alternative splicing in human cancer[J].Cancer Res, 2003,63:655-657.

二级参考文献19

  • 1Tourani JM, Lucas V, Mayeur D, et al. Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma: results of a multieenter SCAPP1 trial. Ann Oneol, 1996, 7:525-528.
  • 2Donskov F, yon der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol, 2006, 24 : 1997-2005.
  • 3Cohen HT, McGovem FJ. Renal-ceU carcinoma. N Engl J Med, 2005, 353:2477-2490.
  • 4Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer, 1997, 80: 1198- 1220.
  • 5Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356:125- 134.
  • 6Motzer R J, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356 : 115-124.
  • 7Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am, 2000, 6 : S55-57.
  • 8Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 1995, 13:688-696.
  • 9Geertsen PF, Gore ME, Negrier S, et al. Safety and efficacy of subcutaneous and continuous intravenous infusion aIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer, 2004, 90: 1156-1162.
  • 10Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs, 2003, 4: 757-763.

共引文献81

同被引文献21

  • 1侯建国,曹广文,李光辉,钱松溪,夏广彬,廖国强,郑家富,张汉升,郑影.联合应用TIL和IL-2治疗肾癌[J].中华泌尿外科杂志,1996,17(5):279-281. 被引量:2
  • 2侯建国,曹广文,李光辉,钱松溪,杨文国,吴宗娣,沈茜,吴金妹,宝建中,郑家富,张汉升,夏广彬.肾细胞癌浸润淋巴细胞的杀伤肿瘤活性测定及表型分析[J].中华泌尿外科杂志,1996,17(2):73-76. 被引量:4
  • 3King S C, Pollack L A, LiJ, KingJ B, Master V A. Continued increase in incidence of renal cell carcinoma, especially in young patients and highgradedisease , United States 2001 to 2010[J].J Urol, 2014,191: 1665- 1670.
  • 4Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas roncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics[J]. Pathol Res Pract,1986,181:125-143.
  • 5Xu X, Hou v , Yin X,Bao L, Tang Av Song Lv et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor[J]. Cell, 2012, 148: 886-895.
  • 6Pena-Llopis S, Vega-Rubin-de-Cells S, Liao A, Leng N, Pavia-Jimenez A. Wang S. et al. BAP1 loss defines a new class of renal cell carcinoma[J]. Nat Genet.2012, 44:751-759.
  • 7SjolundJ ,Johansson M, Manna S, Norin C. Pietras A, Beckman S. et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and vivo[J]J Clin Invest,2008,118:217-228.
  • 8Tan X. He S, Han v, Yu v, XiaoJ, Xu D, et al. Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients[J]. Cancer Cell Int , 2013,13: 20.
  • 9Huang D.Ding Y.Luo W M,Bender S.Qian C N,Kort E, et al. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo[J]. Caner Res.2008,68:81-88.
  • 10Sourbier Cv Lindner V.Lang Hv Agouni Av Schordan E, Danilin S, et al. The phosphorinositide 3-kinase/ AkT pathway: a new target in human renal cell carcinoma therapy[J]. Cancer Res,2006,66:5130-5142.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部